Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

IgG3 Antikörper

Reaktivität: Human WB Wirt: Kaninchen Monoclonal unconjugated
Produktnummer ABIN7267839
  • Target Alle IgG3 Antikörper anzeigen
    IgG3
    Reaktivität
    Human
    Wirt
    • 4
    • 2
    Kaninchen
    Klonalität
    • 5
    • 1
    Monoklonal
    Konjugat
    • 3
    • 1
    • 1
    • 1
    Dieser IgG3 Antikörper ist unkonjugiert
    Applikation
    • 4
    • 2
    Western Blotting (WB)
    Verwendungszweck
    Human IgG3 Rabbit mAb
    Kreuzreaktivität
    Human, Maus, Ratte
    Produktmerkmale
    Monoclonal Antibodies
    Aufreinigung
    Affinity purification
    Immunogen
    A synthesized peptide derived from human Human IgG3
    Isotyp
    IgG
    Top Product
    Discover our top product IgG3 Primärantikörper
  • Applikationshinweise
    WB,1:500 - 1:2000
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    PBS with 0.02 % sodium azide,0.05 % BSA,50 % glycerol, pH 7.3.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store at -20°C. Avoid freeze / thaw cycles.
  • Target
    IgG3
    Andere Bezeichnung
    IGHG3 (IgG3 Produkte)
    Synonyme
    IgG3 antikoerper, Immunoglobulin heavy constant gamma 3 antikoerper, immunoglobulin heavy constant gamma 3 (G3m marker) antikoerper, Ighg3 antikoerper, IGHG3 antikoerper
    Substanzklasse
    Antibody
    Hintergrund
    Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen.,IgG3,Immunology & Inflammation,IGHG3
    Molekulargewicht
    kDa
    Gen-ID
    3502
    UniProt
    P01860
Sie sind hier: